Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU) reported up to 77% tumor growth inhibition with oral elraglusib alone in an aggressive mouse melanoma model. At ENA 2026, the company presented results for the active component of its oral tablet: 50% tumor growth inhibition with once-daily dosing and 77% with twice-daily dosing. Both regimens reduced tumor weight versus the control (P<0.05).
After seven days of treatment, tumors contained more cancer-killing T cells and natural killer cells and fewer potentially immune-suppressing myeloid cells. Actuate plans to start a Phase 1/2 oral tablet trial in Q1 2027, beginning with patients whose metastatic melanoma has not responded to treatment. Modeling suggests the drug exposures linked to antitumor activity in mice may be achievable in humans, but Phase 2 dose selection depends on Phase 1 safety and drug exposure data.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 1/2 oral tablet trial is planned for Q1 2027, starting with patients with refractory metastatic melanoma.
- Minor pointOral elraglusib alone inhibited tumor growth by 50% with once-daily dosing and 77% with twice-daily dosing in mice.
- Minor pointTumor weight fell versus the control with both dosing regimens in mice (P<0.05).
- Minor pointTumor immune cell changes after seven days included more cancer-killing cells and fewer potentially immune-suppressing myeloid cells.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Human drug exposures associated with antitumor activity in mice are projected by modeling, not established in patients.
- Minor point. Forward-looking: it has not happened yet and may not happen.Recommended Phase 2 dose depends on human safety and drug exposure data from Phase 1.
Key Figures
- Tumor growth inhibition
- 50%
- B16F10 melanoma model; once-daily dosing
- Tumor growth inhibition
- 77%
- B16F10 melanoma model; twice-daily dosing
- Tumor weight reduction
- P<0.05
- Both dosing regimens versus control vehicle
- Planned trial initiation
- Q1 2027
- Phase 1/2 trial, beginning with refractory metastatic melanoma patients
Historical Context
-
Previewed oral elraglusib melanoma findings and the planned Q1 2027 Phase 1/2 trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tumor growth inhibition medical
flow cytometry technical
pharmacokinetic medical
recommended phase 2 dose medical
glycogen synthase kinase-3β medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Daily oral elraglusib achieved up to
77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposures - Treatment was associated with changes in the tumor immune microenvironment, characterized by increased cytotoxic T cells and natural killer cells and reduced immunosuppressive myeloid cells
- Findings further reinforce initiation of Phase 1/2 clinical trial in Q1 2027 with daily dosing of elraglusib oral tablet
CHICAGO and FORT WORTH, Texas, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, today announced new preclinical data demonstrating that daily oral administration of elraglusib achieved up to
“These results reinforce our strategy to advance elraglusib as a daily oral therapy and expand its potential applications in oncology,” said Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics. “The exposure-response findings provide valuable insights to inform our upcoming clinical development program, while the observed effects on the tumor immune microenvironment further support the potential of elraglusib as both a monotherapy and in combination with other cancer treatments. We look forward to initiating our Phase 1/2 clinical trial in the first quarter of 2027, beginning with patients with refractory metastatic melanoma.”
From intermittent IV dosing to continuous daily oral therapy
Elraglusib has been developed clinically as an intravenous (IV) infusion administered once or twice weekly, primarily in combination with chemotherapy. That approach includes the randomized Phase 2 trial in metastatic pancreatic cancer in which a once weekly IV infusion of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP alone showed a statistically significant improvement in median overall survival, the primary endpoint in the study. Actuate is now advancing an oral tablet formulation designed for daily dosing. The goal is continuous drug exposure and sustained inhibition of glycogen synthase kinase-3β (GSK-3β), the target through which elraglusib acts on both tumor cells and immune cells.
The poster reports the first in vivo efficacy study of daily oral elraglusib. The study demonstrated significant single-agent antitumor activity with daily oral elraglusib in a preclinical melanoma model, with greater tumor growth inhibition observed at higher drug exposures.
“These findings provide important new insights into the relationship between elraglusib exposure and antitumor activity,” said Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics and presenting author. “In this aggressive melanoma model, we observed greater tumor growth inhibition with increased drug exposure, alongside favorable changes in immune cell populations within the tumor microenvironment. Together, these findings support further investigation of daily oral dosing as a strategy to sustain GSK-3 inhibition and potentially enhance the antitumor activity of elraglusib.”
Key Findings
- Daily oral elraglusib demonstrated greater antitumor activity at higher drug exposures. In mice bearing B16F10 melanoma tumors, elraglusib spray-dried dispersion (SDD), the active component of the Elraglusib Oral Tablet formulation, achieved tumor growth inhibition (TGI) of
50% with once-daily dosing and77% with twice-daily dosing. Both dosing regimens significantly reduced tumor weight compared with those achieved with the control vehicle (P<0.05). - Daily oral elraglusib demonstrated immunomodulatory effects in the tumor microenvironment. A 42-parameter spectral flow cytometry analysis of B16F10 tumors following seven days of treatment showed increased accumulation of cytotoxic CD8+ T cells and natural killer (NK) cells, alongside reductions in Ly6G+ neutrophil/polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-like populations. These findings suggest that daily oral elraglusib may promote a more favorable tumor immune microenvironment by increasing immune effector cell populations while reducing potentially immunosuppressive myeloid cells.
- Preclinical findings inform the planned Phase 1/2 clinical trial. Preclinical exposure-response modeling suggests that drug exposures associated with significant antitumor activity in the B16F10 melanoma model may be achievable in humans with Elraglusib Oral Tablet administered once or twice daily. These projections will inform clinical development, while human pharmacokinetic and safety data from the Phase 1 portion of the planned study will guide dose selection and determination of the recommended Phase 2 dose (RP2D).
Poster Presentation Details
Title: Evaluation of antitumor activity of oral elraglusib in B16F10 melanoma model
Presenting Author: Andrey Ugolkov, MD, PhD, Actuate Therapeutics
Poster Number: PB-142, Exhibition Hall poster area
Session: Translational Studies
Date: November 18, 2026
The poster is available on the Publications page of Actuate’s website at www.actuatetherapeutics.com.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in activation of anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function in addition to targeting those promoting tumor growth and resistance to conventional chemotherapy.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the expectations for the planned Phase 1/2 clinical study of the Elraglusib Oral Tablet based on the results of the Company’s preclinical B16F10 syngeneic melanoma model study; the anticipated timing and design of a Phase 1/2 clinical trial of the Elraglusib Oral Tablet, and the potential benefits of oral elraglusib, including its potential to enhance antitumor activity, improve patient convenience and expand therapeutic applications. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including (i) success in early phases of preclinical clinicals trials do not ensure later clinical trials will be successful, (ii) the risk that we may not be able to commence or complete our expected Phase 1/2 trial of Elraglusib Oral Tablet or, if we can, that the Phase 1/2 trial may not produce positive results; (iii) the risk that the Company may not be able to obtain additional working capital with which to complete the Phase 1/2 clinical trial, or advance to the initiation of registration-enabling studies, for Elraglusib Oral Tablet as and when needed and (iv) those other risks disclosed under the caption “Risk Factors” in Actuate’s Annual Report of Form 10-K filed with the Securities and Exchange Commission on March 26, 2026 and in Actuate’s subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Actuate does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.